1. Safety and efficacy of addition of VEGFR and EGFR-family oral small-molecule tyrosine kinase inhibitors to cytotoxic chemotherapy in solid cancers: A systematic review and meta-analysis of randomized controlled trials
   Tomohiro Funakoshi et al, 2014, Cancer Treatment Reviews CrossRef
2. Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis
   Omar Abdel-Rahman et al, 2015, Expert Review of Anticancer Therapy CrossRef
3. Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis
   Omar Abdel-Rahman et al, 2016, Expert Review of Respiratory Medicine CrossRef